ZDHHC3-mediated SCAP S-acylation promotes cholesterol biosynthesis and tumor immune escape in hepatocellular carcinoma
- Cell Rep. 2024 Nov 9;43(11):114962. doi: 10.1016/j.celrep.2024.114962.
- 1. Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China.
- 2. Division of Hematology/Oncology, Children's Hospital of Pittsburgh of UPMC, Department of Microbiology and Molecular Genetics, Pittsburgh Liver Research Center and Hillman Cancer Center of UPMC, Pittsburgh, PA 15224, USA.
- 3. Department of Laboratory Medicine, Zhongnan Hospital of Wuhan University, Wuhan Research Center for Infectious Diseases and Cancer, Chinese Academy of Medical Sciences, Wuhan, China. Electronic address: [email protected].
- 4. Department of Colorectal and Anal Surgery, Zhongnan Hospital of Wuhan University, Hubei Key Laboratory of Cell Homeostasis, College of Life Sciences, Frontier Science Center for Immunology and Metabolism, Medical Research Institute, TaiKang Center for Life and Medical Sciences, Wuhan University, Wuhan 430071, China. Electronic address: [email protected].
Cholesterol metabolism reprogramming plays essential roles in hepatocellular carcinoma (HCC). However, precisely how Cholesterol metabolism is dysregulated is not clear. Here, we show that the palmitoyltransferase ZDHHC3 and depalmitoylase ABHD17A regulate HCC cell Cholesterol biosynthesis by dynamically S-acylating SREBP cleavage-activating protein (SCAP). SCAP S-acylation by ZDHHC3 at C264 antagonizes HACE1-mediated SCAP ubiquitination. Intriguingly, SREBP2 transcriptionally upregulates ZDHHC3 to form a positive feedback loop, which explains why negative feedback regulation of SCAP/SREBP2 signaling fails in HCC. Increased Cholesterol in the tumor microenvironment (TME) restrains CD4+ T cell cytotoxicity. Hence, the Cholesterol metabolism reprogramming and Cholesterol level alternation in the TME cooperate to promote HCC development. We identified a small-molecule inhibitor of ZDHHC3 that, combined with anti-PD-1 immunotherapy, inhibited diethyl nitrosamine (DEN)/CCl4-induced HCC growth in mice. ZDHHC3-mediated SCAP S-acylation reprograms Cholesterol metabolism and promotes HCC immune escape. ZDHHC3 is thus identified as a rational chemotherapy target for HCC.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
Research Areas: Cancer
-
-
Research Areas: Infection
-
Research Areas: Infection
-
target: P2Y Receptor
-
-
target: Biochemical Assay ReagentsResearch Areas: Cardiovascular Disease
-
target: Biochemical Assay ReagentsResearch Areas: Others
-
target: Proton PumpResearch Areas: Inflammation/Immunology